Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy
Open accessAbstract
Adoptive cell transfer of tumor-infiltrating lymphocytes (TILs) can mediate cancer regression in patients with metastatic melanoma, but whether this approach can be applied to common epithelial malignancies remains unclear. In this study, we compared the phenotype and function of TILs derived from liver and lung metastases from patients with gastrointestinal (GI) cancers (n = 14) or melanoma (n = 42). Fewer CD3+ T cells were found to infiltrate GI compared with melanoma metastases, but the proportions of CD8+ cells, T cell differentiation stage, and expression of costimulatory molecules were similar for both tumor types. Clinical-scale expansion up to ∼50 × 109 T cells on average was obtained for all patients with GI cancer and melanoma. From GI tumors, however, TIL outgrowth in high-dose IL-2 yielded 22 ± 1.4% CD3+CD8+ cells compared with 63 ± 2.4% from melanoma (p < 0.001). IFN-γ ELISA demonstrated MHC class I–mediated reactivity of TIL against autologous tumor in 5 of 7 GI cancer patients tested (9% of 188 distinct TIL cultures) and in 9 of 10 melanoma patients (43% of 246 distinct TIL cultures). In these assays, MHC class I–mediated up-regulation of CD137 (4-1BB) expression on CD8+ cells suggested that 0–3% of TILs expanded from GI cancer metastases were tumor-reactive. This study implies that the main challenge to the development of TIL adoptive cell transfer for metastatic GI cancers may not be the in vitro expansion of bulk TILs, but the ability to select and enrich for tumor-reactive T cells.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For gastrointestinal tumors such as CRC, the primary hurdle in developing TIL therapy may not lie in the in vitro expansion of bulk TILs but rather in the ability to select and enrich tumor-reactive T cells.
“For gastrointestinal tumors, such as CRC, the primary hurdle in developing TIL therapy may not lie in the in vitro expansion of bulk TILs but rather in the ability to select and enrich tumor-reactive T cells [142].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,708 · see citing works
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,145 · see citing works
Self-citationEffector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1× · see citing works
“with aggressive features such as microvascular and perineural invasion compared with tumor with more favorable pathological features (16).”
BackgroundGao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,140 · see citing works
Cancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C. B., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 790 · see citing works
Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200307000-00005 · Cited by 702 · see citing works
Self-citationFukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2003) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532 · see citing works
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.
Schumacher, K., Haensch, W., Röefzaad, C., & Schlag, P. M. (2001) · PubMed · Cited by 503 · see citing works
Besser, M. J., Shapira‐Frommer, R., Treves, A. J., Zippel, D. B., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462 · see citing works
Wölfl, M., Kuball, J. H. E., Ho, W., Nguyen, H., Manley, T. J., Bleakley, M., & Greenberg, P. D. (2007) · Blood · doi:10.1182/blood-2006-11-056168 · Cited by 460 · see citing works
Radvanyi, L., Bernatchez, C., Zhang, M.-Y., Fox, P., Miller, P. W., Chacon, J. A., Wu, R. C., Lizée, G., Mahoney, S. L., Alvarado, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1177 · Cited by 423 · see citing works
Itoh, K., Platsoucas, C. D., & Balch, C. M. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.4.1419 · Cited by 323 · see citing works
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 312 · see citing works
Self-citationPrognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
Lee, H. E., Chae, S. W., Lee, Y. J., Kim, M., Lee, H. S., Lee, B. L., & Kim, W. H. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604738 · Cited by 302 · see citing works
Watson, N. F., Ramage, J. M., Madjd, Z., Spendlove, I., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2005) · International Journal of Cancer · doi:10.1002/ijc.21303 · Cited by 254 · see citing works
Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
Wu, R. C. H., Forget, M., Chacon, J. A., Bernatchez, C., Haymaker, C., Chen, J. Q., Hwu, P., & Radvanyi, L. G. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d4465 · Cited by 248 · see citing works
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 243 · see citing works
Self-citationDudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y. K., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6441 · Cited by 236 · see citing works
Self-citationAngiogenesis as an unfavorable prognostic factor in human colorectal carcinoma
Takebayashi, Y., Akiyama, S., Yamada, K., Akiba, S., & Aikou, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960715)78:2 · Cited by 222 · see citing works
Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression
Chattopadhyay, P. K., Yu, J., & Roederer, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.1 · Cited by 201 · see citing works
Ellebæk, E., Iversen, T. Z., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L. R., Andersen, R. S., Hadrup, S. R., Andersen, M. H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-169 · Cited by 172 · see citing works
Katz, S. C., Bamboat, Z. M., Maker, A. V., Shia, J., Pillarisetty, V. G., Yopp, A. C., Hedvat, C. V., Gönen, M., Jarnagin, W. R., Fong, Y., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2668-9 · Cited by 171 · see citing works
Kawakami, Y., Rosenberg, S. A., & Lotze, M. T. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.6.2183 · Cited by 163 · see citing works
Self-citationClinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
Ferdinande, L., Decaestecker, C., Verset, L., Mathieu, A., Lopez, X. M., Negulescu, A.-M., Maerken, T. V., Salmon, I. J., Cuvelier, C. A., & Demetter, P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.513 · Cited by 148 · see citing works
Immune regulation and control of regulatory T cells by OX40 and 4-1BB
So, T., Lee, S., & Croft, M. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.04.003 · Cited by 145 · see citing works
Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D. J., Wunderlich, J. R., Merino, M. J., & Rosenberg, S. A. (2008) · Blood · doi:10.1182/blood-2008-06-163048 · Cited by 141 · see citing works
Self-citationKatz, S. C., Pillarisetty, V. G., Bamboat, Z. M., Shia, J., Hedvat, C. V., Gönen, M., Jarnagin, W. R., Fong, Y., Blumgart, L. H., D'Angelica, M. I., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0585-3 · Cited by 136 · see citing works
Heo, D. S., Whiteside, T. L., Johnson, J. T., Chen, K. N., Barnes, E. L., & Herberman, R. B. (1987) · PubMed · Cited by 128 · see citing works
Clinical significance of immune cell infiltration within gallbladder cancer
Nakakubo, Y., Miyamoto, M., Cho, Y., Hida, Y., Oshikiri, T., Suzuoki, M., Hiraoka, K., Itoh, T., Kondo, S., & Katoh, H. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601331 · Cited by 117 · see citing works
Kono, K., Takahashi, A., Ichihara, F., Amemiya, H., Iizuka, H., Fujii, H., Sekikawa, T., & Matsumoto, Y. (2002) · PubMed · Cited by 111 · see citing works
Translational Applications of Flow Cytometry in Clinical Practice
Jaye, D. L., Bray, R. A., Gebel, H. M., Harris, W. A. C., & Waller, E. K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1290017 · Cited by 109 · see citing works
Weber, J. S., Atkins, M. B., Hwu, P., Radvanyi, L. G., Sznol, M., & Yee, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2272 · Cited by 87 · see citing works
Dendritic cells, T-cell infiltration, and grp94 expression in cholangiocellular carcinoma
TAKAGI, S. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.03.016 · Cited by 86 · see citing works
Immunotherapy for metastatic solid cancers
Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81 · see citing works
Self-citationPrieto, P. A., Durflinger, K. H., Wunderlich, J. R., Rosenberg, S. A., & Dudley, M. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d367bd · Cited by 78 · see citing works
Self-citationSpecific and non-specific lymphocyte cytotoxicity in colon carcinoma
Vose, B. M., Gallagher, P., Moore, M., & Schofield, P. F. (1981) · British Journal of Cancer · doi:10.1038/bjc.1981.283 · Cited by 69 · see citing works
Hom, S. S., Rosenberg, S. A., & Topalian, S. L. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01789124 · Cited by 64 · see citing works
Self-citationWang, Y. L., Si, L. S., KANBOUR, A. I., Herberman, R. B., & Whiteside, T. L. (1989) · PubMed · Cited by 60 · see citing works
Shimizu, Y., Iwatsukï, S., Herberman, R. B., & Whiteside, T. L. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01789045 · Cited by 42 · see citing works
Watanabe, K., Suzuki, S., Kamei, M., Toji, S., Kawase, T., Takahashi, T., Kuzushima, K., & Akatsuka, Y. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0134-z · Cited by 42 · see citing works
Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
Maccalli, C., Li, Y. F., El‐Gamil, M., Rosenberg, S. A., & Robbins, P. F. (2003) · PubMed · Cited by 31 · see citing works
Self-citationHan, S.-H., Huang, Y.-J., Liang, Y., Ho, Y.-Y., Wang, Y., & Chang, L.-J. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-34 · Cited by 19 · see citing works
Flagged first, then by citations
4 of the 49 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,710 · see citing works
Self-citationPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,113 · see citing works
Self-citationLauss, M., Donia, M., Harbst, K., Andersen, R. S., Mitra, S., Rosengren, F., Salim, M., Vallon‐Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 481 · see citing works
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466 · see citing works
Self-citationTumor organoid–T-cell coculture systems
Cattaneo, C. M., Dijkstra, K. K., Fanchi, L. F., Kelderman, S., Kaing, S., van Rooij, N., van den Brink, S., Schumacher, T. N., & Voest, E. E. (2020) · Nature Protocols · doi:10.1038/s41596-019-0232-9 · Cited by 410 · see citing works
Connolly, K. A., Kuchroo, M. R., Venkat, A., Khatun, A., Wang, J., William, I., Hornick, N. I., Fitzgerald, B., Damo, M., Kasmani, M. Y., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg7836 · Cited by 403 · see citing works
Adoptive cellular therapies: the current landscape
Rohaan, M. W., Wilgenhof, S., & Haanen, J. B. A. G. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2484-0 · Cited by 400 · see citing works
Principles of adoptive T cell therapy in cancer
Met, Ö., Mølgaard, K., Chamberlain, C. A., Donia, M., & Svane, I. M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0703-z · Cited by 213 · see citing works
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Stoiber, S., Cadilha, B. L., Benmebarek, M.-R., Lesch, S., Endres, S., & Kobold, S. (2019) · Cells · doi:10.3390/cells8050472 · Cited by 180 · see citing works
Seo, H., Jeon, I., Kim, B., Park, M. H., Bae, E., Song, B., Koh, C., Shin, K., Kim, I., Choi, K.-Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms15776 · Cited by 164 · see citing works
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
Hall, M. S., Liu, H., Malafa, M. P., Centeno, B. A., Hodul, P. J., Pimiento, J. M., Pilon‐Thomas, S., & Sarnaik, A. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0164-7 · Cited by 164 · see citing works
Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies
Deniger, D. C., Maiti, S. N., Mi, T., Switzer, K. C., Ramachandran, V., Hurton, L. V., Ang, S., Olivares, S., Rabinovich, B. A., Huls, M. H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3451 · Cited by 132 · see citing works
Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer
Foppen, M. H. G., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.018 · Cited by 130 · see citing works
Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future
Warner, A. B., Corrie, P. G., & Hamid, O. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1922 · Cited by 131 · see citing works
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
Halse, H. M., Colebatch, A. J., Petrone, P., Henderson, M. A., Mills, J. K., Snow, H. A., Westwood, J. A., Sandhu, S. K., Raleigh, J., Behren, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28944-3 · Cited by 122 · see citing works
Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients
Egelston, C. A., Avalos, C., Tu, T. Y., Rosario, A., Wang, R., Solomon, S. T., Srinivasan, G., Nelson, M. S., Huang, Y., Lim, M. H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130000 · Cited by 114 · see citing works
Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
Bertrand, F., Rochotte, J., Colacios, C., Montfort, A., Tilkin-Mariamé, A.-F., Touriol, C., Rochaix, P., Lajoie-Mazenc, I., Andrieu-Abadie, N., Levade, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2524 · Cited by 113 · see citing works
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
Manfredi, F., Cianciotti, B. C., Potenza, A., Tassi, E., Noviello, M., Biondi, A., Ciceri, F., Bonini, C., & Ruggiero, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01689 · Cited by 105 · see citing works
An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors
Lu, Y., Zheng, Z., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Li, Y. F., Ray, S., Franco, Z., Bliskovsky, V. V., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.018 · Cited by 101 · see citing works
Self-citationGlioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy
Klein, E., Hau, A., Oudin, A., Golebiewska, A., & Niclou, S. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.604121 · Cited by 98 · see citing works
Zheng, Y., Li, Y., Lian, J., Yang, H., Li, F., Zhao, S., Qi, Y., Zhang, Y., & Huang, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1917-0 · Cited by 100 · see citing works
Feldman, S. A., Assadipour, Y., Kriley, I. R., Goff, S. L., & Rosenberg, S. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.005 · Cited by 96 · see citing works
Self-citationCell Tracking in Cancer Immunotherapy
Perrin, J., Capitao, M., Mougin‐Degraef, M., Guérard, F., Faivre-Chauvet, A., Rbah‐Vidal, L., Gaschet, J., Guilloux, Y., Kraeber‐Bodéré, F., Chérel, M., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00034 · Cited by 77 · see citing works
Andersen, R. S., Westergaard, M. C. W., Kjeldsen, J. W., Müller, A., Pedersen, N. W., Hadrup, S. R., Met, Ö., Seliger, B., Kromann‐Andersen, B., Hasselager, T., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0467 · Cited by 73 · see citing works
Zhu, G., Nemoto, S., Mailloux, A. W., Perez-Villarroel, P., Nakagawa, R., Falahat, R., Berglund, A., & Mulé, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01609 · Cited by 76 · see citing works
Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy
Kodumudi, K. N., Siegel, J., Weber, A. M., Scott, E. N., Sarnaik, A. A., & Pilon‐Thomas, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153053 · Cited by 74 · see citing works
Mardiana, S., John, L. B., Henderson, M. A., Slaney, C. Y., von Scheidt, B., Giuffrida, L., Davenport, A. J., Trapani, J. A., Neeson, P. J., Loi, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1831 · Cited by 74 · see citing works
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer
Thibaudin, M., Limagne, E., Hampe, L., Ballot, E., Truntzer, C., & Ghiringhelli, F. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03182-9 · Cited by 70 · see citing works
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
Lowery, F. J., Goff, S. L., Gasmi, B., Parkhurst, M. R., Ratnam, N. M., Halas, H. K., Shelton, T. E., Langhan, M. M., Bhasin, A., Dinerman, A. J., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03627-5 · Cited by 68 · see citing works
Self-citationTumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy
Turcotte, S., Gros, A., Tran, E., Lee, C. R., Wunderlich, J. R., Robbins, P. F., & Rosenberg, S. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1736 · Cited by 63 · see citing works
Self-citationCancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 61 · see citing works
Sakellariou-Thompson, D., Forget, M., Creasy, C. A., Bernard, V., Zhao, L., Kim, Y. U., Hurd, M. W., Uraoka, N., Parra, E. R., Kang, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0831 · Cited by 60 · see citing works
Seo, H., Kim, B. S., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0708 · Cited by 58 · see citing works
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 57 · see citing works
Multifaceted modes of action of the anticancer probiotic Enterococcus hirae
Goubet, A.-G., Wheeler, R., Fluckiger, A., Qu, B., Lemaître, F., Iribarren, K., Mondragón, L., Tidjani Alou, M., Pizzato, E., Durand, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00753-8 · Cited by 54 · see citing works
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine
Rimassa, L., Personeni, N., Aghemo, A., & Lleò, A. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.03.007 · Cited by 54 · see citing works
The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.
Neal, L. R., Bailey, S. R., Wyatt, M. M., Bowers, J. S., Majchrzak, K., Nelson, M. H., Haupt, C., Paulos, C. M., & Varela, J. C. (2017) · PubMed · Cited by 52 · see citing works
Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours
Chruściel, E., Urban‐Wójciuk, Z., Arcimowicz, Ł., Kurkowiak, M., Kowalski, J., Gliwiński, M., Marjański, T., Rzyman, W., Biernat, W., Dziadziuszko, R., et al. (2020) · Cancers · doi:10.3390/cancers12030683 · Cited by 51 · see citing works
Yunger, S., El, A. B., Zeltzer, L., Fridman, E., Raviv, G., Laufer, M., Schachter, J., Markel, G., Itzhaki, O., & Besser, M. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1672494 · Cited by 47 · see citing works
Checkpoints and beyond – Immunotherapy in colorectal cancer
Gutting, T., Burgermeister, E., Härtel, N., & Ebert, M. P. A. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.003 · Cited by 46 · see citing works
T-cell-based breast cancer immunotherapy
Pilipow, K., Darwich, A., & Losurdo, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.019 · Cited by 44 · see citing works
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Golinelli, G., Dominici, M., Grisendi, G., Spano, C., Rossignoli, F., & Prapa, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0422-y · Cited by 45 · see citing works
The tumour immune landscape and its implications in cutaneous melanoma
Attrill, G. H., Ferguson, P. M., Palendira, U., Long, G. V., Wilmott, J. S., & Scolyer, R. A. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12926 · Cited by 40 · see citing works
Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma
Mallone, F., Sacchetti, M., Lambìase, A., & Moramarco, A. (2020) · Cancers · doi:10.3390/cancers12102761 · Cited by 40 · see citing works
Malignant melanoma—The cradle of anti-neoplastic immunotherapy
Koller, K. M., Wang, W., Schell, T. D., Cozza, E. M., Kokolus, K. M., Neves, R. I., Mackley, H. B., Pameijer, C. R., Leung, A. M., Anderson, B. E., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.010 · Cited by 39 · see citing works
Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential
Jiménez-Reinoso, A., Nehme-Álvarez, D., Domínguez-Alonso, C., & Álvarez‐Vallina, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.593848 · Cited by 38 · see citing works
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works
Kroemer, M., Turco, C., Spehner, L., Viot, J., Idirène, I., Bouard, A., Renaude, E., Deschamps, M., Godet, Y., Adotévi, O., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001478 · Cited by 37 · see citing works
CD137+ T-Cells: Protagonists of the Immunotherapy Revolution
Ugolini, A., & Nuti, M. (2021) · Cancers · doi:10.3390/cancers13030456 · Cited by 36 · see citing works
Hurtado, M. O., Wolbert, J., Fisher, J. P. H., Flutter, B. R., Stafford, S., Barton, J., Jain, N., Barone, G., Majani, Y., & Anderson, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216373 · Cited by 32 · see citing works
Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 31 · see citing works
Itoh, T., Kawai, Y., Yasui, Y., Iriguchi, S., Minagawa, A., Ishii, T., Miyoshi, H., Taketo, M. M., Kawada, K., Obama, K., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02195-x · Cited by 29 · see citing works
Advances and Prospects in Cancer Immunotherapy
Zhou, J. (2014) · New Journal of Science · doi:10.1155/2014/745808 · Cited by 28 · see citing works
Okamura, K., Nagayama, S., Tate, T., Chan, T., Kiyotani, K., & Nakamura, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03444-1 · Cited by 27 · see citing works
Generation of colon cancer–derived tumor-infiltrating T cells (TILs) for adoptive cell therapy
Albrecht, H. C., Gustavus, D., Schwanemann, J., Dammermann, W., Lippek, F., Weylandt, K. H., Hoffmeister, H., & Gretschel, S. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.01.009 · Cited by 27 · see citing works
Sim, G. C., Chacon, J. A., Haymaker, C., Ritthipichai, K., Singh, M. P., Hwu, P., & Radvanyi, L. G. (2014) · BioDrugs · doi:10.1007/s40259-014-0097-y · Cited by 26 · see citing works
Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?
Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973881 · Cited by 24 · see citing works
Ding, M., Fei, Y., Zhu, J., Ma, J., Zhu, G., Zhen, N., Zhu, J., Mao, S., Sun, F., Wang, F., et al. (2022) · Cancer Science · doi:10.1111/cas.15374 · Cited by 21 · see citing works
Targeting TNF alpha as a novel strategy to enhance CD8+T cell-dependent immune response in melanoma?
Bertrand, F. A., Rochotte, J., Colacios, C., Montfort, A., Andrieu‐Abadie, N., Levade, T., Benoist, H., & Ségui, B. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1068495 · Cited by 21 · see citing works
Chen, M., Xu, G., Fan, M., Jia, H., Xiao, L., & Lang, J. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1687498 · Cited by 19 · see citing works
Beha, N., Harder, M. J., Ring, S., Kontermann, R. E., & Müller, D. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1204 · Cited by 18 · see citing works
Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
Nagayama, S., Low, S., Kiyotani, K., & Nakamura, Y. (2021) · Cancers · doi:10.3390/cancers13194803 · Cited by 15 · see citing works
Novel Treatments in Development for Melanoma
Bernatchez, C., Cooper, Z. A., Wargo, J. A., Hwu, P., & Lizee, G. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_16 · Cited by 15 · see citing works
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14 · see citing works
Chen, I., Mathews-Greiner, L., Li, D., Abisoye-Ogunniyan, A., Ray, S., Bian, Y., Shukla, V., Zhang, X., Guha, R., Thomas, C. J., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1197-5 · Cited by 14 · see citing works
Current Status of Immunotherapy Treatments for Pancreatic Cancer
Jiménez‐Luna, C., Prados, J. C., Ortíz, R., Melguizo, C., Torres, C., & Caba, O. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000623 · Cited by 13 · see citing works
Surgical immune interventions for solid malignancies
Zeltsman, M., Mayor, M., Jones, D. R., & Adusumilli, P. S. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.06.008 · Cited by 13 · see citing works
PD-1 inhibitors dependent CD8+ T cells inhibit mouse colon cancer cell metastasis
Gao, C., Zhang, M., Song, Q., & Dong, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s202941 · Cited by 11 · see citing works
Immunotherapy in Upper GI Malignancies
Murphy, A. G., & Kelly, R. J. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0336-6 · Cited by 11 · see citing works
Generation of Tumor-activated T cells Using Electroporation
Alinezhadbalalami, N., Graybill, P. M., Imran, K. M., Verbridge, S. S., Allen, I. C., & Davalos, R. V. (2021) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2021.107886 · Cited by 10 · see citing works
Potential advantages of CD1-restricted T cell immunotherapy in cancer
Consonni, M., Dellabona, P., & Casorati, G. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.09.025 · Cited by 10 · see citing works
Lundberg, J., Jussing, E., Liu, Z., Meng, Q., Rao, M., Samén, E., Grankvist, R., Damberg, P., Dodoo, E., Maeurer, M. J., et al. (2016) · Cell Transplantation · doi:10.3727/096368916x693347 · Cited by 9 · see citing works
Emerging role of immunotherapy in urothelial carcinoma—Future directions and novel therapies
Park, J., & Hahn, N. M. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.09.002 · Cited by 8 · see citing works
Comparative phenotypes of peripheral blood and spleen cells from cancer patients
Cole, K., Ly, Q. P., Hollingsworth, M. A., Cox, J. L., Stromnes, I. M., Padussis, J. C., Foster, J. M., Vargas, L. M., & Talmadge, J. E. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106655 · Cited by 8 · see citing works
Einstein, D. J., Halbert, B. T., Denize, T., Matar, S., West, D. J., Gupta, M., Andrianopoulos, E., Seery, V. J., Herman, C., Onimus, K., et al. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000533 · Cited by 7 · see citing works
Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions
Bot, A. I., Marincola, F. M., & Smith, K. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836908 · Cited by 7 · see citing works
Vrecko, S., Guenat, D., Mercier‐Letondal, P., Faucheu, H., Dosset, M., Royer, B., Galaine, J., Boidot, R., Kim, S. C. H., Jary, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26247 · Cited by 7 · see citing works
Ren, L., Matsuda, T., Deng, B., Kiyotani, K., Kato, T., Park, J.-H., Seiwert, T. Y., Vokes, E. E., Agrawal, N., & Nakamura, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23454 · Cited by 7 · see citing works
Baek, J., Choi, G., Lee, G., Lee, H., Gong, G., Park, H. S., Kim, J. Y., Kim, J. Y., & Lee, H. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-85892-5 · Cited by 5 · see citing works
Miamen, A. G., Gustafson, M. P., & Roberts, L. R. (2014) · Hepatology · doi:10.1002/hep.27442 · Cited by 4 · see citing works
Expansion and characterization of tumor-infiltrating lymphocytes from human sarcoma
Hall, M. S., Mullinax, J. E., Royster, E. B., Reagan, A., Gonzalez, R. J., Pimiento, J. M., Pilon‐Thomas, S., & Sarnaik, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p19 · Cited by 3 · see citing works
Cutaneous Cell- and Gene-Based Therapies for Inherited and Acquired Skin Disorders
Chamcheu, J. C., Adhami, V. M., Siddiqui, I. A., & Mukhtar, H. (2015) · CRC Press eBooks · doi:10.1201/b18002-52 · Cited by 3 · see citing works
Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects
Sarker, D. B., González, M., Martinez, S., & Sang, Q. A. (2025) · Visualized Cancer Medicine · doi:10.1051/vcm/2025010 · Cited by 2 · see citing works
Immunotherapy for Resected Pulmonary Metastases
Morse, M. A. (2015) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2015.09.009 · Cited by 2 · see citing works
Immune microenvironment and progress in immunotherapy of cholangiocarcinoma
Shao, X. (2023) · Clinical Immunology Communications · doi:10.1016/j.clicom.2023.11.002 · Cited by 1 · see citing works
Kuznetsova, D. V., & Petrova, T. V. (2025) · Acta Naturae · doi:10.32607/actanaturae.27559 · Cited by 1 · see citing works
Folsom, T. D., Moriarity, B. S., Starr, T. K., Lou, E., & Webber, B. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00005-7 · Cited by 1 · see citing works
Sipuleucel-T – A Model for Immunotherapy Trial Development
Slovin, S. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00056-6 · Cited by 1 · see citing works
Okamura, K., Nagayama, S., Tate, T., Chan, H. T., Kiyotani, K., & Nakamura, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1374720/v1 · Cited by 1 · see citing works
Plachynta, M. (2015) · Cell and Organ Transplantology · doi:10.22494/cot.v3i1.20
Improving adenovirus-based immunotherapies for treatment of solid tumors
Siurala, M. (2017) · Työväentutkimus Vuosikirja
Adoptive Cell Therapy of Gastric Cancer
Zou, Z., Zhao, L., Ren, Y., & Du, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-3978-2_11
Personalized Medicine in Oncology Drug Development
Dracopoli, N. C., Grewal, I. S., Takimoto, C. H. M., & Lebowitz, P. F. (2019) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm052.pub2
Immune Therapy for Central Nervous System Metastasis
McAvoy, M. B., Choi, B. D., & Jones, P. S. (2020) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2020.06.014
Expansion of tumor-infiltrating lymphocytes with substantial stem cell properties from vulvar cancerPreprint
Yao, T., & Liu, Y. (2021) · doi:10.22541/au.163155045.52606364/v1
Current State of Cell Therapies for Gastrointestinal Cancers
Kooragayala, K., Lou, J., & Hong, Y. K. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000611
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.c.6548926.v1
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.c.6548926
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.22538878.v1
Yao, T., Shi, Z., Sun, J., Wang, Y., Zhou, H., Chen, Y., Zhou, D., Lin, Z., & Liu, Y. (2023) · Journal of Vaccines Immunology and Immunopathology · doi:10.29011/2575-789x.000190
- Authors
- Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-01
- Volume
- 191
- Issue
- 5
- Pages
- 2217-2225
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC3748336
- OpenAlex
- W2142257845
- Cited by
- 107
- References
- 49
- Citations by year
- 2025: 5 · 2024: 2 · 2023: 7 · 2022: 10 · 2021: 11 · 2020: 10 · 2019: 12 · 2018: 12 · 2017: 11 · 2016: 7 · 2015: 11 · 2014: 6 · 2013: 3
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-infiltrating lymphocytes, adoptive cell transfer, metastatic melanoma, gastrointestinal cancer, liver metastasis, lung metastasis, CD8+ T cells, T cell differentiation, costimulatory molecules, CD137 (4-1BB), T cell expansion
- MeSH terms
- Female, Flow Cytometry, Gastrointestinal Neoplasms, Humans, Immunohistochemistry, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Phenotype, T-Lymphocytes, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
